simply diluting the reaction medium, once TLC monitor-
ing indicated that the intermolecular addition of xanthate
8b to alkenes 15 and 19 was essentially complete, and
adding portionwise a stoichiometric amount of lauroyl
peroxide.
Scheme 7. Access to Spirocyclic and Fused Tricyclic Structures
Bicyclic pyrimidine derivatives such as 17 and, espe-
cially, 21 are rare and hitherto not readily available core
structures.16 The expedient access to complex derivatives,
only tediously available by conventional ionic or organo-
metallic routes, is further illustrated by the synthesis of
spiro derivative 38fromxanthate37displayed inScheme 7.
The radical cyclization step proved remarkably efficient in
this case, and the precursor alkenes 35 and 36 are readily
available using known chemistry.17
Finally, the incorporation of various functional groups
contained in the xanthate partner and the presence of the
two chlorines on the pyrimidine ring provide a simple
means for constructing another ring by an ionic process.
Compounds 17a and 21a may thus be converted into the
novel tricyclic compounds 40 and 41 after cleavage of the
phthalimido group with hydrazine. This cyclization failed
with 12a presumably because of increased strain in the
expected product 39.
In summary, apart from highlighting a facile route to
polycyclic pyrimidine and, to a lesser extent, pyridine
derivatives, this study has revealed a relatively rare situa-
tion where the formation of a five-membered ring is much
less efficient than the corresponding ring closure leading to
six- and seven-membered rings.18
peroxide and solvent are used in both steps; only the con-
centration differs. Thus, 17b and 21b were obtained in
comparable overall yield, 41% and 34% respectively, by
(15) The slower abstraction of deuterium, because of the primary
kinetic isotope effect, has been exploited to circumvent synthetic hurdles
caused by unwanted intramolecular hydrogen atom shifts: (a) Wood,
Acknowledgment. This paper is dedicated with respect
to the memory of Professor Alessandro Degl’Innocenti
(University of Florence). We thank Ecole Polytechnique
and Master Ile-de-France/Fudan University for scholar-
ships to Z.L. and L.Q.
ꢁ ꢁ
M. E.; Bissiriou, S.; Lowe, C.; Norrish, A. M.; Senechal, K.; Windeatt,
K. M.; Coles, S. J.; Hursthouse, M. B. Org. Biomol. Chem. 2010, 8, 4653.
(b) Wood, M. E.; Bissiriou, S.; Lowe, C.; Windeatt, K. M. Org. Biomol.
Chem. 2008, 6, 3048. (c) Clive, D. L. J.; Cantin, M.; Khodabocus, A.;
Kong, X.; Tao, Y. Tetrahedron 1993, 49, 7917. (d) Clive, D. L. J.; Tao,
Y.; Khodabocus, A.; Wu, Y. -J.; Angoh, A. G.; Bennett, S. M.; Boddy,
C. N.; Bordeleau, L.; Kellner, D.; Gleiner, G .; Middleton, D. S.; Nichols,
C. J.; Richardson, S. R.; Vernon, P . G. J. Am. Chem. Soc. 1994, 116, 11275.
(16) (a) El Kaım, L.; Grimaud, L.; Oble, J. J. Org. Chem. 2007, 72,
¨
Supporting Information Available. Experimental pro-
cedures, full spectroscopic data, and copies of 1H and 13
NMR spectra for all new compounds. This material is
org.
5835. (b) LaLonde, R. T.; El-Kafrawy, A.; Muhammad, N.; Oatis, J. E., Jr.
J. Org. Chem. 1977, 42, 1808. (c) Kuyper, L. F.; Garvey, J. M.; Baccanari,
D. P.; Champness, J. N.; Stammers, D. K.; Beddell, C. R. Bioorg. Med.
Chem. 1996, 4, 593. (d) Gossett, L. S.; Habeck, L. L.; Shackelford, K. A.;
Mendelsohn, L. G.; Gates, S. B.; Worzalla, J. F.; Self, T. D.; Theobald, K. S.;
Andis, S. L.; Schultz, R. M.; Shih, C. Bioorg. Med. Chem. Lett. 1999, 9, 75.
(e) St-Denis, Y.; Di Fabio, R.; Bernasconi, G.; Castiglioni, E.; Contini, S.;
Donati, D.; Fazzolari, E.; Gentile, G.; Ghirlanda, D.; Marchionni, C.;
Messina, F.; Micheli, F.; Pavone, F.; Pasquarello, A.; Sabbatini, F. M.;
Zampori, M. G.; Arban, R.; Vitulli, G. Bioorg. Med. Chem. Lett. 2005, 15,
3713. (f) Provins, L.; Christophe, B.; Danhaive, P.; Dulieu, J.; Durieu, V.;
C
(17) (a)Sugiura, M.;Hirano, K.;Kobayashi, S. J. Am. Chem. Soc. 2004,
126, 7182. (b) Dhudshia, B.; Tiburcio, J.; Thadani, A. N. Chem. Commun.
2005, 41, 5551The modest yield of precursor 36 is due to competing
substitution at the 2-position of the 2,4,6-trichloropyrimidine ring.
(18) For another related instance, see ref 10e.
ꢁ
ꢁ ꢁ
Gillard, M.; Lebon, F.; Lengele, S.; Quere, L.; van Keulen, B. Bioorg. Med.
Chem. Lett. 2006, 16, 1834. (g) Morita, K.; Kobayashi, S.; Shimadzu, H.;
Ochiai, M. Tetrahedron Lett. 1970,11, 861. (h) Boger, D. L.; Kochanny, M. J.
J. Org. Chem. 1994, 59, 4950.
The authors declare no competing financial interest.
Org. Lett., Vol. 14, No. 23, 2012
5979